Recent News

• 03.07.2025 - Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent
• 03.07.2025 - Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent
• 01.22.2025 - Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies
• 01.22.2025 - Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies
• 12.31.2024 - Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
• 12.31.2024 - Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
• 12.20.2024 - Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
• 12.20.2024 - Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
• 10.04.2024 - Altamira Therapeutics Provides Update on Nasdaq Listing
• 09.27.2024 - Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

Recent Filings

• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.20.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.20.2024 - EX-99.1 EX-99.1
• 11.14.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors
• 10.04.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]